Functional mannose-binding lectin levels in patients with end-stage renal disease on maintenance hemodialysis

Atsushi Satomura, Takayuki Fujita, Mitsuru Yanai, Kazunari Kumasaka, Yuki Uehara, Kazuyoshi Okada, Yoshinobu Fuke, Tomohiro Nakayama

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: Innate immunity is generally impaired in chronic renal failure (CRF). Mannose-binding lectin (MBL) has an important role in first-line host defense against pathogens via the lectin pathway. We recently reported that functional MBL was significantly lower in CRF patients than in healthy subjects. In this study, we aimed to determine whether functional MBL would be improved following hemodialysis (HD) therapy. Methods: This study included 22 patients with end-stage renal disease (ESRD) on maintenance HD. Functional MBL was measured every 6 months for 1 year after HD using an enzyme-linked immunosorbent assay. Results: Median serum functional MBL levels of ESRD patients were significantly higher after 6 and 12 months than at the start of HD therapy (p < 0.05 and p < 0.01, respectively). Furthermore, median functional MBL levels at 12 months were significantly higher than those at 6 months (p < 0.05). Conclusions: We found significant increases in serum functional MBL levels in patients on HD. Our results indicated that HD tailored to remove uremic toxins could improve functional MBL levels in these patients.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalJournal of Innate Immunity
Issue number3
Publication statusPublished - 04-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy


Dive into the research topics of 'Functional mannose-binding lectin levels in patients with end-stage renal disease on maintenance hemodialysis'. Together they form a unique fingerprint.

Cite this